NCT02517320View on ClinicalTrials.gov

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
Diabetic Nephropathy
Interventions
DRUG

MT-3995 Low

DRUG

MT-3995 Middle

DRUG

MT-3995 High

DRUG

Placebo

Trial Locations (1)

Unknown

Investigational site, Hokkaido

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY